0LC7.L
SYROS PHARMACEUTICALS INC SYROS
£0.00
+0.00%
2026-05-29
About SYROS PHARMACEUTICALS INC SYROS
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Key Fundamentals
EPS (TTM)
£-1.55
ROE
-777.0%
Profit Margin
0.0%
Price/Book
-0.00
Beta
1.26
Avg Volume (10D)
813
Recent Breakout Signals
No recent breakout signals detected for 0LC7.L.
Recent Price Range (60 Days)
60D High
£0.00
60D Low
£0.00
Avg Volume
5K
Latest Close
£0.00
Get breakout alerts for 0LC7.L
Sign up for Breakout Scanner to receive daily notifications when 0LC7.L triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
SYROS PHARMACEUTICALS INC SYROS (0LC7.L) is listed on the London Stock Exchange (LSE). Breakout Scanner monitors 0LC7.L daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups.. Data is provided for informational purposes only and does not constitute financial advice.